title: Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.
abstract: Fragile X syndrome (FXS) results from dynamic mutations leading ultimately to the absence of expression of the Fragile X Mental Retardation Protein (FMRP). It is characterized by synaptic upregulated protein synthesis and immature dendritic spines associated with altered brain plasticity and cognitive functions. Recent work in Fmr1 knockout mice has shown that lovastatin, an inhibitor of Ras-ERK1/2, normalized hippocampus protein synthesis. We hypothesize that lovastatin, as a disease-modifying drug, would counterweigh the absence of FMRP and improve behavior. Here we report a phase I study to assess the safety and efficacy of lovastatin in individuals with FXS. A total of 15 patients (13 males, 6-31 years old) were treated with escalating doses of lovastatin (up to 40 mg) for three months. Their behavior were assessed before and after treatment using the Aberrant Behavioral Checklist--Community (ABC-C) total score (primary outcome), as well as domains of the FXS validated version of the ABC-C (secondary outcomes). The treatment was well tolerated and minimal side effects were reported. Significant improvement in the primary outcome (P<0.005), as well as in secondary outcomes, were observed in the majority of the subjects (12/15). We think that long-term sustained treatment with diseased-modifying drugs would be necessary in order to improve behavior and ultimately learning. Lovastatin, well known for its long-term security profile, would be a good candidate for that purposes. Our study showing reassuring safety data along with potential functional benefit emphasizes the need of a placebo-controlled trial to ascertain lovastatin efficacy in FXS individuals.
authors.affiliation: Department of Biochemistry, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
authors.forename: Artuela
authors.initials: A
authors.lastname: Çaku
authors.forename: David
authors.initials: D
authors.lastname: Pellerin
authors.forename: Paméla
authors.initials: P
authors.lastname: Bouvier
authors.forename: Emilie
authors.initials: E
authors.lastname: Riou
authors.forename: Francois
authors.initials: F
authors.lastname: Corbin
mesh_terms: D000293:Adolescent; D000328:Adult; D001519:Behavior / Q000187:drug effects*; D002648:Child; D005260:Female; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics; D005600:Fragile X Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000523:psychology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D008148:Lovastatin / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D009154:Mutation; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D051860:Fragile X Messenger Ribonucleoprotein 1; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008148:Lovastatin
keywords: ERK pathway; behavior; clinical trial; fragile X syndrome; hyperactivity; intellectual disability; lovastatin; open-label study